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Abstract
The major histocompatibility complex (MHC) on chromosome 6 is associated with susceptibility
to more common diseases than any other region of the human genome, including almost all
disorders classified as autoimmune. In type 1 diabetes the major genetic susceptibility
determinants have been mapped to the MHC class II genes HLA-DQB1 and HLA-DRB1 (refs
1-3), but these genes cannot completely explain the association between type 1 diabetes and the
MHC region4-11. Owing to the region’s extreme gene density, the multiplicity of disease-
associated alleles, strong associations between alleles, limited genotyping capability, and
inadequate statistical approaches and sample sizes, which, and how many, loci within the MHC
determine susceptibility remains unclear. Here, in several large type 1 diabetes data sets, we
analyse a combined total of 1,729 polymorphisms, and apply statistical methods—recursive
partitioning and regression—to pinpoint disease susceptibility to the MHC class I genes HLA-B
and HLA-A (risk ratios>1.5; Pcombined=2.01×10-19 and 2.35×10-13, respectively) in addition to the
established associations of the MHC class II genes. Other loci with smaller and/or rarer effects
might also be involved, but to find these, future searches must take into account both the HLA
class II and class I genes and use even larger samples. Taken together with previous
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studies4-8,10-16, we conclude that MHC-class-I-mediated events, principally involving HLA-B*39,
contribute to the aetiology of type 1 diabetes.
The MHC spans 4 megabases (Mb) and contains 149 genes, of which eight (the class II loci
HLA-DRB1, HLA-DQB1, HLA-DQA1, HLA-DPB1, HLA-DPA1; the class I loci HLA-A,
HLA-B and HLA-C) are the highly polymorphic immune response genes. There are many
other candidate genes with common variants—any one of which or a combination thereof—
that might also be involved in disease susceptibility. We studied 850 type-1-diabetes-
affected sibling-pair (ASP) families from the United Kingdom and the United States and a
first set of 2,049 type 1 diabetes patients and 1,912 controls from across Great Britain, in
which we genotyped a combined total of 254 polymorphic MHC loci, including HLA-
DQB1, HLA-DRB1, HLA-A and HLA-B (Table 1 and Supplementary Table 1). A second
independent set of 1,050 type 1 diabetes cases and 1,125 controls was used for validation.
After these analyses were completed, 1,475 additional single nucleotide polymorphisms
(SNPs) in 1,964 of our type 1 diabetes cases and 2,923 controls became available as part of
our collaboration with the Wellcome Trust Case Control Consortium (WTCCC)17 (Table
1).
As expected1-3,18, the strongest type 1 diabetes associations mapped to the MHC class II
genes HLA-DQB1 and HLA-DRB1 (P=10-117 and P=10-124, respectively, for the genotype
model in the families, and similarly, P<10-300 and P=10-300, respectively, in the first case–
control set; Fig. 1 and Supplementary Table 2, see also http://dil.t1dbase.org/page/poster/
mhc_association). The data did not fit the multiplicative model owing to the known epistatic
interactions between alleles and dominance effects of HLA-DRB1 and HLA-DQB1
genotypes2,19.
There was evidence for a secondary peak of type 1 diabetes association around HLA-B
(P=3.44×10-30 and 3.59×10-42, in the families and the case–control set, respectively; Fig. 1
and Supplementary Table 2). To test whether these were MHC-class-II-independent effects,
or merely reflected linkage disequilibrium with class II, we had to use a method that takes
into account the complex multi-allelic effects of the highly disease-associated HLA-DQB1
and HLA-DRB1 genes. We compared three strategies for grouping class II genotypes in our
families (Supplementary Results). The P-value for the test locus, conditional on the class II
genotypes, was, at some loci, dependent on the method adopted for grouping the class II loci
(Supplementary Results and Supplementary Table 3). Hence, these methods were
unsatisfactory and we adopted a classification tree approach, namely, recursive
partitioning20-22 (http://cran.r-project.org). This is a risk-categorization method of grouping
that differs from other risk-based grouping methods because it does not require the risk to be
known a priori. The method classifies individuals as affected or unaffected using their class
II genotypes by carrying out a series of binary splits on the basis of those class II genotypes,
such that homogeneity with respect to disease status (risk) is maximized for each group
while retaining good statistical power (see Methods). In contrast to other grouping methods
considered, the recursive partitioning model provided consistent results (Supplementary
Table 3).
In the families, using the optimized tree model, we found evidence of an additional effect of
HLA-B (P=4.19×10-7), HLA-DPB1 (P=2.21×10-5) and of a SNP in the TAP2 gene
(rs241448, P=5.29×10-5; Fig. 1 and Supplementary Table 2). In the case–control set, we
again found evidence of an independent effect of HLA-B (P=1.74×10-7) over and above the
combined effect of HLA-DQB1 and HLA-DRB1, as well as an independent effect of HLA-
A (P=1.67×10-10). No evidence was obtained for independent effects of the 169 non-
synonymous (ns)SNPs, or the seven candidate SNPs (P>0.001, Fig. 1 and Supplementary
Table 2). Specifically, no evidence was found for association of the TAP2 SNP (rs241448,
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P=0.074), the recently reported ITPR3 SNP23 (rs2296336), nor for the UBD and MAS1L
gene regions24 (Supplementary Results and Supplementary Table 2).
After conditioning on HLA-B, HLA-DRB1 and HLA-DQB1, we had 49% power to find an
effect of odds ratio 2.0 in the first case–control set, assuming a minor allele frequency of 0.1
at α=1×10-5 with HLA-B, HLA-DRB1 and HLA-DQB1 in the model (Supplementary
Methods). Hence, we conditioned on HLA-B, HLA-DRB1 and HLA-DQB1, obtaining
evidence that HLA-A was independently associated with type 1 diabetes (P=2.31×10-7), as
was rs4151651 (P=8.13×10-5), a nsSNP in the complement factor B (CFB) gene. However,
we only had 13% power to test for additional associations to HLA-B, HLA-DRB1 and
HLA-DQB1 in our 850 families, probably accounting for our failure to detect the HLA-A
association in these families. So we sought to replicate the HLA-A result in an independent
1,050 cases and 1,125 controls (Table 1, second case–control set), obtaining convincing
confirmatory evidence at P=1.77×10-5 after conditioning on both HLA-DRB1 and HLA-
DQB1 (Supplementary Table 4).
Having taken into account the combined effect of HLA-DQB1 and HLA-DRB1, as above,
we found that the HLA-B*39 allele (where * represents the allele) was consistently
associated with type 1 diabetes susceptibility (relative risk=3.55 (95% confidence interval
2.21–5.72) in the families; odds ratio=2.41 (95% confidence interval 1.49–3.89) in the first
case–control set; Table 2 and Supplementary Table 5). Moreover, HLA-B*39 was also
associated with a lower age-at-diagnosis of type 1 diabetes in the families (P=0.0022) and in
the cases from the first case–control set (P=0.0021; Supplementary Table 5). Once the
association of HLA-B*39 was taken into account, there was no association of other HLA-B
alleles in the families (P=0.047). Nevertheless, in the first case–control set HLA-B*18
conferred susceptibility to and HLA-B*27 protection from type 1 diabetes (Table 2 and
Supplementary Table 5). These HLA-B allele associations were still present after
conditioning on HLA-A as well as HLA-DRB1 and HLA-DQB1 combined (Table 2).
In the first case–control set, having conditioned on HLA-DQB1, HLA-DRB1 and HLA-B
using allele HLA-A*02 as a reference, HLA-A*01, HLA-A*11 and HLA-A*31 were
protective and HLA-A*24 was predisposing for type 1 diabetes; HLA-A*03 was more
predisposing than HLA-A*11 and HLA-A*31 (Supplementary Table 4). Once these alleles
were accounted for, there was no further detectable HLA-A effect in the case–control set
(P=0.15). In the second case–control set, having conditioned on HLA-DRB1 and HLA-
DQB1, both HLA-A*01 and HLA-A*11 were again more protective than HLA-A*02. HLA-
A*24 was still the most predisposing for type 1 diabetes and may also be associated with an
earlier age-at-diagnosis (P=0.01; Supplementary Tables 4 and 5).
Finally, the SNPs from the WTCCC17 scan were analysed for association with type 1
diabetes. The 20 most associated SNPs all lay within the MHC class II region, with the most
associated locus, rs9273363, close to HLA-DQB1 (P=4.29×10-298 in 1,964 cases and 2,923
controls; Fig. 2 and Supplementary Table 6; see also http://dil.t1dbase.org/page/poster/
mhc_association). Once the effects of HLA-DRB1 and HLA-DQB1 are accounted for, the
polymorphisms in the MHC class I region provide the strongest signals of association in the
1,281 cases and 860 controls genotyped at HLA-DRB1, HLA-DQB1 and the WTCCC SNPs
(Fig. 2 and Supplementary Table 6). The most associated locus became rs3130531, located
~40 kilobases telomeric of HLA-C (P=6.74×10-7 compared with P=0.0056 before
conditioning). Once HLA-DRB1, HLA-DQB1 and HLA-B were conditioned on, however,
none of the WTCCC SNPs were convincingly associated with type 1 diabetes (Fig. 2 and
http://dil.t1dbase.org/page/poster/mhc_association).
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Nevertheless, to increase our statistical power, we genotyped the eight WTCCC SNPs most
associated with type 1 diabetes, after HLA-DRB1 and HLA-DQB1 conditioning, in a larger
set of 2,484 cases and 2,019 controls with complete HLA-DRB1 and HLA-DQB1
genotyping. The most associated locus was rs9268831 (P=6.95×10-8; Supplementary Table
6); note that this was less significant than either HLA-B or HLA-A, which remained the
most associated loci in the same data set after class II genes were accounted for
(P=3.80×10-17 and 4.59×10-15, respectively; Supplementary Table 6). This SNP, located
~15 kb centromeric of HLA-DRA, was still associated once HLA-B was included in the
model (P=5.44×10-6). In contrast, the SNP rs3130531 at 31.3 Mb was not associated in this
data set after conditioning on HLA-DRB1, HLA-DQB1 and HLA-B (P=0.16;
Supplementary Table 6).
Our results indicate that, once the effect of the MHC class II genes has been accounted for,
most of the detectable residual association is attributable to HLA-B and HLA-A (combining
all data sets, Pcombined = 2.01×10-19 and 2.35×10-13, respectively). We conclude that the
existence of other major type 1 diabetes genes in the extended MHC is unlikely. Smaller
independent effects, however, might still exist, necessitating future studies including
analysis of rs9268831 (HLA-DRA), rs4151651 (CFB), HLA-C, HLA-DQA1 and the HLA-
DP loci. The HLA-B and HLA-A alleles have previously been associated with type 1
diabetes4,5,8,10,11, but unlike these previous studies, our results localize the effects to these
specific loci and alleles, thereby implicating them directly in disease aetiology.
In the nonobese diabetic mouse model of type 1 diabetes, MHC class I molecules and class-
I-restricted CD8+ T cells are central to the development of autoimmune diabetes12-14. This
correlates with the observations that in type 1 diabetes patients, cells infiltrating pancreatic
islets are predominantly CD8+ and islet cells hyperexpress MHC class I molecules15,16.
Taken together with our results, we conclude that class-I-mediated anti-islet β-cell responses
are critical in type 1 diabetes and may accelerate disease onset. This might involve both the
innate and adaptive immune system25,26. The HLA-A*02 allotype has been functionally
and directly linked to T-cell autoreactivity to insulin27, and our results now justify
investigation of the naturally processed peptides that bind the HLA-B*39 allotype as a first
step towards future evaluation of inducing tolerance to such peptides in attempts to prevent
type 1 diabetes.
METHODS SUMMARY
A detailed description of the methods is given in Methods and Supplementary Information.
All subjects were of white ethnicity: 850 families came from established collections; 4,126
cases were Juvenile Diabetes Research Foundation/Wellcome Trust type 1 diabetes cases
and 4,394 were British 1958 Birth Cohort controls. The classical loci were typed using
Dynal RELI SSO assays. All loci conformed to Hardy–Weinberg equilibrium in unaffected
subjects. Family data were analysed using cases with matched pseudo-controls in regression
models. Stepwise logistic regression28 was used to test for effects independent of HLA-
DRB1 and HLA-DQB1. The class II genotypes (rather than the alleles of HLA-DRB1 and
HLA-DQB1 which do not behave multiplicatively in conferring type 1 diabetes risk) were
modelled using a recursive partitioning approach20-22 (http://cran.r-project.org). These
groups created by recursive partitioning, define strata within which additional loci can be
tested. Pruning of the tree, that is, assessing how much of the tree to retain, was done by
cross-validation29. Although when to stop pruning the tree was unclear, the number of
leaves (HLA-DQB1/HLA-DRB1 groups) must be sufficient to prevent residual
confounding, but not so great as to become inestimable. The recursive partitioning model
was assessed using a third locus. The non-class-II loci were modelled as multiplicative
effects of alleles. All analyses of the case–control set were stratified by broad geographical
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region17,30. Power to detect effects independent of HLA-DRB1 and HLA-DQB1 was
assessed using data sets simulated from the case–pseudo-control data (and separately from
the case–control set). Crucially the groupings from the recursive partitioning model were
retained. A total of 100,000 replicates were performed. The Wald test was used to assess
significance and subsequently the power of the study. We had 49% power to detect odds
ratio=2.0 for an allele frequency of 0.1 at α=1×10-5 in the case–control set with HLA-
DRB1, HLA-DQB1 and HLA-B in the model. We set a threshold of P<0.0001 for rejection
of H0.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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APPENDIX
METHODS
Subjects
The family set comprised 850 type 1 diabetes families of white ethnicity with both parents
and at least two affected children in each family, including 472 Warren type 1 diabetes
families from the United Kingdom (11 with only one affected offspring) and 378 Human
Biological Data Interchange (HBDI) type 1 diabetes families from the United States (five
with only one affected offspring). The case–control sample comprised 4,126 type 1 diabetes
patients collected as part of the JDRF/WT DIL British type 1 diabetes case collection (http://
www-gene.cimr.cam.ac.uk/ucdr/grid.shtml) and 4,394 controls selected from the British
1958 Birth Cohort of people born in England, Scotland and Wales during 1 week in 1958
(http://www.b58cgene.sgul.ac.uk). Of these individuals, 2,049 cases and 1,912 controls were
typed at the classical MHC loci. A further 1,445 controls were from the WTCCC’s UK
Blood Service samples17. The relevant research ethics committees approved the study, and
written informed consent was obtained from the participants, or their parents/guardian for
those too young to consent.
Grouping of HLA-DRB1 and HLA-DQB1 alleles and genotypes: recursive partitioning
In the families, cases and matched pseudo-controls were generated28 and the matching
discarded so as to be able to run recursive partitioning in the recursive partitioning library in
R (http://cran.r-project.org; refs 20-22). Cases and pseudo-controls were matched when
doing later analyses. The alleles of HLA-DRB1 and HLA-DQB1 do not behave
multiplicatively in conferring type 1 diabetes risk, so, to allow for dominance effects, the
genotypes of the individual loci were modelled, as this does not assume a specific mode of
inheritance. All possible binary splits of the data corresponding to presence or absence of
various different genotypes at HLA-DRB1 and HLA-DQB1 were considered. The split that
best categorized the data as cases and pseudo-controls, which corresponds to the split that
maximizes the reduction in impurity (or maximizes the homogeneity of the cases or pseudo-
controls within groups), was chosen. We chose the information index, which has the form
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f(p) = -2plog(p) (where p = the proportion of observations in a node that for future samples
belong to a different class) as the impurity measure because it is likelihood based. This
process was repeated until no further improvement could be made or the minimum group
size was met. The terminal ‘leaves’ of the tree represent optimized groups of the HLA-
DQB1/HLA-DRB1 genotypes and so define strata within which additional MHC loci can be
tested. However, the trees generated are often complex and need to be pruned. Pruning of
the tree, that is, assessing how much of the tree to retain, was done by cross-validation29.
Nevertheless, when to stop pruning the tree was unclear, the number of leaves (HLA-
DQB1/-DRB1 groups) must be sufficient to prevent residual confounding, but not so great
as to become inestimable.
Pruning and evaluation of the HLA-DQB1/HLA-DRB1 trees
Initially, we used the TAP2 SNP rs241448 to assess the appropriateness of the HLA-DRB1
and HLA-DQB1 tree models and subsequently used an additional 14 loci (Supplementary
Table 3). As the number of terminal leaves (HLA-DRB1/-DQB1 groups) in the model
increases, we expect the effect size of the additional locus to decrease as confounding is
reduced, while the 95% confidence interval will become larger (Supplementary Fig. 1). This
information can be used to optimize the choice of tree by considering the best compromise
between number of terminal leaves (groups of HLA-DRB1 and HLA-DQB1 genotypes),
effect size and 95% confidence interval. By adding the TAP2 SNP rs241448, we tested each
of the possible six pruned HLA-DRB1/HLA-DQB1 trees (that corresponded to different
complexity parameters) in the family data set. The greatest disparity in effect size was seen
between the two models with the minimum number of terminal leaves (four and seven
groups) with relative risk = 0.7 (95% confidence interval 0.5–0.9) and the remainder with
between 12 and 22 groups, relative risk = 0.6 (95% confidence interval 0.5–0.8). The effect
size and 95% confidence interval at this locus was stable with respect to the number of
terminal leaves (that is, HLA-DRB1/-DQB1 groups). Therefore, using the TAP2 SNP only,
the 12 group model appeared to be the best compromise between effect size, 95%
confidence interval and number of groups (that is, complexity of the model). Nevertheless,
to verify that the number of groups used for the MHC class II model would not affect the
interpretation of results, we tested the remaining 14 loci used to evaluate other grouping
methods (Supplementary Results) for association, conditioning on class II effects using each
of the four tree models with 12 or greater terminal leaves (Supplementary Table 3). The 12
group model exhibited one inconsistent result at MICA compared to all the other recursive
partitioning models (P = 0.0005 versus P > 0.05), otherwise all loci tested were stable with
respect to the number of groups in the model (Supplementary Table 3). Hence, the model
with 16 terminal leaves was chosen to model the confounding effects of HLA-DRB1 and
HLA-DQB1: this model had the minimum number of groups that gave results consistent
with both the 18 group model and the 22 group model at all loci.
We did not use this 16 group model for the case–control collection because the way in
which the two sample sets were ascertained could affect their MHC associations. The ASP
families are likely to be enriched for HLA susceptibility haplotypes compared to isolated
cases. They were also collected over 10 years earlier, during which time the incidence of
type 1 diabetes has increased, and have a higher average age-at-diagnosis (12 years)
compared to the British cases (7 years). We did, however, use the same approach to
choosing the optimal tree model for the cases and controls as for the families. The MHC
class II genotypes were put into the recursive partitioning library. The maximum number of
groups obtained was 14 (which corresponded to a complexity parameter of 0). Of the five
pruned HLA-DRB1/HLA-DQB1 trees possible (corresponding to different complexity
parameters) the model with 12 terminal leaves was the best compromise between effect size
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and 95% confidence interval, gave consistent results across loci and was very similar to the
tree with the maximum 14 terminal leaves.
The effect sizes with corresponding 95% confidence intervals are given in Supplementary
Table 7 for the case–control model and the model used for the families, using an
approximately neutral group as reference. Note that although the tree used for the families
has 16 groups, one of these groups only contains pseudo-controls and so is not used for the
analysis. Similarly one of the 12 groups used for the case–control set consisted of just 13
cases, which are dropped from the association analysis.
We then assessed the effectiveness of the HLA-DRB1/HLA-DQB1 tree model. Hence, we
generated 1,000 bootstrap sample data sets, with replacement, within geographical and case–
control strata. Four loci were used as the non-class-II test locus and analysed in each data
set: the TAP2 SNP rs241448; the UBD SNP rs389419; the HLA-DRA SNP rs9268831; and
the HLA-B Bw4/Bw6 epitope polymorphism. Supplementary Fig. 1 shows a plot of the
regression coefficient for the test locus rs9268831 against number of groups for each
bootstrap data set. Notably, although the effect size decreases (that is, the regression
coefficient increases) with number of groups, this decrease was very modest, indicating that
our effect size estimates are good. We then used the bootstrap samples to calculate 95%
confidence intervals for each test locus. Reassuringly, all bootstrap 95% confidence intervals
were consistent with the original 95% confidence intervals (rs241448, 95% CIorig = 0.66–
1.02 and 95% CIboot = 0.71–1.17; rs389419, 95% CIorig = 1.13–1.59 and 95% CIboot =
1.17–1.84; rs9268831, 95% CIorig = 0.62–0.83 and 95% CIboot = 0.57–0.80; HLA-B Bw4/
Bw6, 95% CIorig = 1.02–1.45 and 95% CIboot = 1.003–1.45) and do not lead to a different
interpretation of results. Hence, we believe that the trees are effective models for the HLA-
DRB1/HLA-DQB1 effects.
Testing for associations at non-class-II loci in families
We specifically wished to test the hypothesis that loci within the MHC were associated with
type 1 diabetes independently of the highly associated class II genes HLA-DRB1 and HLA-
DQB1. Owing to the complex relationship between these two genes, extensive linkage
disequilibrium and epistatic interaction effects2, we believed that a joint model was required
to explain the observed association. This approach was justified because both loci were
necessary to partition the data within recursive partitioning.
Forward stepwise conditional logistic regression was used to test whether any of the 83 loci
typed in the MHC had an effect in addition to the HLA class II DRB1/DQB1 effect28. Only
individuals typed at both the class II loci and the test locus were used for the stepwise
analysis. The HLA-DRB1/HLA-DQB1 loci (modelled using the recursive partitioning
method described above) were placed in the regression model as confounders and other loci
added; whether or not a non-HLA-DRB1/HLA-DQB1 locus improved on the model was
tested by a Wald test where robust variance estimates could be applied, or else by a
likelihood ratio test. The non-HLA-DRB1/HLA-DQB1 loci were modelled as alleles when
the multiplicative model was appropriate, and genotypes otherwise.
Testing for non-HLA-DRB1/HLA-DQB1 loci in the case–control collection
As with the family data set, HLA-DRB1 and HLA-DQB1 were grouped by recursive
partitioning (detailed above) and placed in the logistic regression model as confounders. A
likelihood ratio test was used to test whether other loci added to the regression model. P <
0.0001 was considered significant. The analysis was stratified both by broad geographical
region30 and by the HLA-DRB1/HLA-DQB1 groups. The most significant locus was added
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as alleles or genotypes to the grouped class II loci and other loci added to them to test for
additional effects.
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Figure 1. Association analyses across the MHC
a, b, -log10(P) versus chromosome position. Unconditional single locus analyses are
presented for loci typed in up to 850 families (a) and in up to 2,049 cases and 1,125 controls
(b, first case–control set). c, d, Analyses conditional on HLA-DRB1 and HLA-DQB1 in the
families (c) and in the first case–control set (d). Results are listed in Supplementary Tables 1
and 2.
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Figure 2. Association analyses of 1,475 SNPs across the MHC
a, Unconditional single locus analysis in up to 1,964 cases and 2,923 controls—the limits of
the association are at 25.9 Mb (rs1324088 P=4.65×10-6) and 34.0 Mb (rs6941621
P=9.95×10-6). b, c, Results are presented in up to 1,281 cases and 860 controls for analyses
conditioned on HLA-DRB1 and HLA-DQB1 combined (annotated SNPs were followed up
in a larger case–control set; Supplementary Table 6) (b), and for analyses conditioned on
HLA-DRB1 and HLA-DQB1 combined and the alleles of HLA-B with frequency >0.01 (c).
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Table 1
Data sets used to test for unconditional single locus and MHC-class-II-independent type 1 diabetes
associations in the MHC
Data set Size of data set Classical MHC genes genotyped
in data set
SNPs and microsatellite
markers genotyped in data set
Family set 850 affected sibling-pair (ASP)
families from
the United Kingdom and the United
States
HLA-DQB1, HLA-DRB1, HLA-
DQA1,
HLA-DPB1, HLA-A, HLA-B and
HLA-C*
27 microsatellites;
46 SNPs in candidate genes†
First case–control set 2,049 type 1 diabetes patients and
1,912
controls from Great Britain
HLA-DQB1, HLA-DRB1, HLA-A
and
HLA-B*
7 SNPs in the candidate genes‡;
169 nsSNPs from the GWA
scan§
Second case–control set
(for validation of the
HLA-A association)
Additional 1,050 type 1 diabetes
patients
and 1,125 controls from Great Britain
HLA-DQB1, HLA-DRB1 and
HLA-A
Not applicable
WTCCC case–control set 1,964 type 1 diabetes patients and
2,923
controls—overlaps with the main case–
control set in 1,281 type 1 diabetes
cases
and 860 controls
HLA-DQB1, HLA-DRB1, HLA-A
and
HLA-B: available for 1,281 type 1
diabetes patients and 860 controls
1,475 SNPs from WTCCC GWA
scan
WTCCC follow-up
case–control set
2,484 type 1 diabetes patients and
2,019
controls
HLA-DQB1, HLA-DRB1, HLA-A
and
HLA-B
The eight most class-II-
independently-
associated SNPs from the
WTCCC scan
*See Supplementary Table 1.
†
Forty-six newly typed SNPs from fifteen candidate immune genes in or near the MHC (ITPR3, HLA-DPB1, HLA-DMA, HLA-DMB, PPP1R2P1,
TAP1, TAP2, HLA-DOB, BTNL2, C6orf25, LY6G6C, NCR3, TNFA, LTA and NFKBIL1).
‡SNPs rs241447 and rs241448 from TAP2, rs1800750 from TNFA, and rs2296336, rs3131020, rs1233478 and rs389419 in the recently reported
type-1-diabetes-associated genes ITPR3 (ref. 23), UBD and MAS1L (ref. 24).
§One-hundred-and-sixty-nine nsSNPs were part of a genome-wide association (GWA) scan of over 12,000 nsSNPs30, spanning the entire 10-Mb
extended MHC region. These SNPs were analysed in the case–control set and an additional 2,077 type 1 diabetes patients and 2,482 controls from
Great Britain that were not typed at the MHC class II loci.
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